CAMP4 Therapeutics (NASDAQ:CAMP) Director Andrew Schwab Sells 114,700 Shares

CAMP4 Therapeutics Corporation (NASDAQ:CAMP) Director Andrew Schwab sold 114,700 shares of the company’s stock in a transaction that occurred on Thursday, August 20th. The stock was sold at an average price of $4.54, for a total transaction of $520,738.00. Following the sale, the director directly owned 2,465,298 shares in the company, valued at approximately $11,192,452.92. The trade was a 4.45% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

CAMP4 Therapeutics Stock Performance

Shares of CAMP opened at $4.48 on Friday. The stock has a 50-day simple moving average of $4.12 and a 200-day simple moving average of $4.34. The stock has a market capitalization of $281.12 million, a PE ratio of -1.93 and a beta of 0.22. CAMP4 Therapeutics Corporation has a 1 year low of $1.41 and a 1 year high of $7.75.

CAMP4 Therapeutics (NASDAQ:CAMP) last issued its earnings results on Thursday, August 13th. The Wireless communications provider reported ($0.58) EPS for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.34). The firm had revenue of $1.78 million for the quarter. CAMP4 Therapeutics had a negative return on equity of 252.79% and a negative net margin of 2,543.74%. Analysts predict that CAMP4 Therapeutics Corporation will post -0.59 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on the company. UBS Group set a $15.00 price target on CAMP4 Therapeutics in a research report on Friday, August 14th. Piper Sandler reissued an “overweight” rating and issued a $15.00 target price (up from $12.00) on shares of CAMP4 Therapeutics in a report on Friday, August 14th. JPMorgan Chase & Co. upgraded CAMP4 Therapeutics from a “neutral” rating to an “overweight” rating and upped their price target for the stock from $5.00 to $9.00 in a research note on Tuesday, June 16th. Weiss Ratings upgraded shares of CAMP4 Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, August 14th. Finally, Zacks Research raised shares of CAMP4 Therapeutics from a “strong sell” rating to a “hold” rating in a report on Monday, August 17th. Seven investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $9.56.

Hedge Funds Weigh In On CAMP4 Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Jupiter Topco LLC purchased a new stake in shares of CAMP4 Therapeutics in the second quarter valued at about $27,581,000. Janus Henderson Group PLC raised its position in shares of CAMP4 Therapeutics by 35.9% during the 4th quarter. Janus Henderson Group PLC now owns 6,307,636 shares of the Wireless communications provider’s stock worth $38,807,000 after purchasing an additional 1,666,666 shares during the last quarter. 5AM Venture Management LLC acquired a new position in shares of CAMP4 Therapeutics during the 2nd quarter worth approximately $25,647,928,000. Vivo Capital LLC lifted its stake in CAMP4 Therapeutics by 8.3% in the 4th quarter. Vivo Capital LLC now owns 4,246,568 shares of the Wireless communications provider’s stock valued at $26,031,000 after buying an additional 325,000 shares in the last quarter. Finally, Balyasny Asset Management L.P. acquired a new stake in CAMP4 Therapeutics during the 4th quarter valued at $14,938,000.

CAMP4 Therapeutics Company Profile

CalAmp Corp., a connected intelligence company, provides leverages a data-driven solutions ecosystem to people and organizations in the United States, Europe, the Middle East, Africa, Latin America, the Asia-Pacific, and internationally. The company operates in two segments, Software & Subscription Services and Telematics Products. It provides CalAmp Telematics Cloud platform, such as cloud-based application enablement and telematics service platforms that facilitate integration of its own applications, as well as those of third parties, through open application programming interfaces; and software as a service application, as well as provides tracking and monitoring services within fleet management, supply chain integrity, and international vehicle location.